Search Bar & Filters
Found 51 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease through a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study. The study includes a 40-week pivotal maintenance sub-study followed by a 240-week open-label extension sub-study, with a total duration of up to 286 weeks. Participants must have previously responded to treatment and completed endoscopy in a prior study phase. Participants receive subcutaneous injections of duvakitug or placebo according to the study protocol during the maintenance period. Those who complete the maintenance sub-study may continue in the open-label extension sub-study for longer-term treatment and monitoring. The treatment duration can be up to 280 weeks, including both study periods, with a total of up to 43 on-site visits planned. Throughout the trial, participants attend regular visits for assessments including clinical remission measured by the Crohns Disease Activity Index CDAI, endoscopic response, and patient-reported outcomes. Safety is monitored by tracking adverse events and antidrug antibody development. After treatment, participants have a 45-day follow-up visit. The study evaluates outcomes at Week 40 and continues monitoring throughout the extension period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of duvakitug in people with moderately to severely active Ulcerative Colitis UC. This Phase 3, multicenter, randomized, double-blind, placebo-controlled maintenance study aims to understand how well duvakitug works to maintain clinical remission and improve symptoms in participants with UC. The trial is sponsored by Sanofi and includes a large, diverse participant group aged 16 to 80 years. Participants receive subcutaneous injections of either one of three doses of duvakitug or a placebo following the study protocol. The study consists of two main periods a 40-week Pivotal Maintenance Sub-Study and a 240-week Open-Label Extension OLE Sub-Study. Those who do not join the OLE will complete a 45-day follow-up after the maintenance phase. Across both periods, participants may have up to 32 on-site visits to monitor treatment and health status. During the study, participants will undergo various assessments including endoscopy, clinical response evaluations, and symptom scoring by modified Mayo Score. Researchers will monitor clinical remission, endoscopic and histologic improvements, corticosteroid use, fatigue, abdominal pain, quality of life, and hospitalization incidence. Safety will be closely tracked through adverse event reporting and measurement of drug concentration and immune response. The total participation duration can be up to 286 weeks, allowing long-term monitoring of duvakitugs effects.
Actively Recruiting
This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.
Actively Recruiting
Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.
Actively Recruiting
Researchers are evaluating the efficacy and safety of FT819, a treatment made of allogeneic T cells expressing a CD19-targeted CAR, for people with moderate-to-severe systemic lupus erythematosus SLE who have lupus nephritis LN that has not responded to at least two prior immunosuppressive treatments. This phase 2, open-label, single-arm trial focuses on participants aged 12 to 70 with biopsy-proven Class III or IV LN and active disease. The study aims to measure how many participants achieve complete renal response at 26 weeks. Participants will first undergo a screening period lasting up to 28 days. After screening, they will receive bendamustine treatment followed by a single intravenous infusion of FT819. The study will include efficacy, safety, and exploratory assessments at scheduled timepoints through 24 months of post-treatment follow-up. After this, participants will be monitored for safety and survival for up to 15 years in a long-term follow-up phase. Throughout the study, researchers will assess lupus nephritis activity using standard measures, including complete and partial renal responses, and clinician-reported outcomes such as SLEDAI-2K, BILAG, and PGA scores. Safety and disease activity evaluations will take place at predefined visits. The total duration of participation includes multiple assessments during the first two years and extended long-term monitoring up to 15 years to observe ongoing effects and survival.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of claseprubart in adults with generalized myasthenia gravis gMG in this Phase 3 study. The trial aims to demonstrate how claseprubart affects daily living activities and muscle strength in participants diagnosed with gMG. Participants are randomly assigned to receive either an intravenous IV loading dose of claseprubart or placebo on Day 1, followed by subcutaneous SC injections of claseprubart or placebo every two weeks starting at Week 1. The study includes a screening period of up to 12 weeks, a 17-week randomized, blinded, controlled treatment period, an optional extended treatment period lasting 104 weeks with blinded and open-label extensions, and a 40-week safety follow-up phase. During the study, participants undergo various assessments including the Myasthenia Gravis Activities of Daily Living MG-ADL scale, Quantitative Myasthenia Gravis QMG scale, and Myasthenia Gravis Composite MGC scale. Researchers also monitor treatment-emergent adverse events, serum concentrations of claseprubart, complement blood test changes, and antibody development against the drug. The total participation can last up to approximately 161 weeks, covering all study phases and follow-up.
Actively Recruiting
Researchers are evaluating efimosfermin alfa in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis MASH and stage F2 or F3 liver fibrosis. The study aims to assess the safety and effectiveness of efimosfermin alfa compared to a placebo in resolving steatohepatitis and improving liver-related clinical outcomes. This Phase 3 trial is randomized, double-blind, and placebo-controlled, focusing on participants with specific liver conditions and metabolic syndrome components. Participants are assigned to one of three groups two groups receive different dose levels of efimosfermin alfa, while the third group receives a placebo. Treatments are given under controlled conditions, and the study follows a parallel design. The trial monitors participants at set intervals over a course of 52 weeks, with some outcomes tracked up to 48 months to evaluate long-term effects on liver fibrosis and steatohepatitis. During the study, participants undergo liver biopsies to confirm diagnosis and assess changes. Researchers evaluate improvements in fibrosis stage, steatohepatitis resolution, and various liver function measurements using imaging and blood tests. Safety is monitored by tracking adverse events and laboratory abnormalities. Quality of life and other health indicators are also assessed throughout the study, which lasts several years to capture both short- and long-term outcomes.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether a new active rehabilitation program can improve recovery outcomes for soldiers who have experienced mild traumatic brain injury mTBI, also known as concussion. The study aims to test if this active rehab approach helps soldiers return to duty faster and improves their cognitive and physical function. The research is conducted in a military setting and involves comparing current standard care with the new active rehab method. The study involves two groups of soldiers stationed at Fort Bragg, North Carolina, who have had an mTBI within the past two weeks. One group receives the current progressive return to activity PRA care, while the other group follows the Active Rehab protocol, which includes personalized activities such as low-intensity aerobic exercise, cognitive tasks, balance training, and visualvestibular exercises. This rehab is progressed based on symptoms and duty needs over five phases, aiming to accelerate safe recovery. The intervention is delivered by trained providers, and outcomes from both groups are compared. Participants will be assessed at initial intake, two weeks post-enrollment, when asymptomatic, and upon clearance to return to full duty. Evaluations include military performance, heart rate variability, cognitive tests, coordination, symptom inventories, and quality of life measures. The study will follow participants for up to about a year to track recovery progress. Data collected will help develop a clinical algorithm to guide future active rehab for military personnel after mTBI.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.
1-10 of 51
1